MRP1 and MRP2, founding members of the MRP family, are involved in cellular resistance to anticancer agents and drug disposition in the body. Studies in our laboratory and others now indicate that the MRP family extends to 9 members. In the previous funding period we focused on the analysis of the in vivo functions of MRP3 and MRP4, and on the elucidation of the functional properties of MRP6, MRP7 and MRP8. To accomplish this we developed and analyzed mrp3 and mrp4 knock-out mice and cell lines in which MRP6, MRP7 and MRP8 were ectopically expressed. Using our mrp3 knock-out mice, we showed that the Mrp3 functions in liver as a basolateral efflux pump for sulfate metabolites of xenobiotics, and that it similarly protects cholestatic liver from endogenous compounds such as bile acids. Our studies on Mrp4 knockout mice showed that Mrp4 is an in vivo resistance factor for the antiviral nucleotide analog PMEA, restricts penetration of this agent into brain, and like Mrp3, functions in the basolateral extrusion of sulfates from hepatocytes. MRP6, MRP7 and MRP8 were determined to be lipophilic anion transporters that are able to confer cellular resistance to anticancer natural product (MRP6, MRP7) and nucleoside-based agents (MRP8). In this application we propose to define the pharmacological functions of MRP4 as an in vivo resistance factor for anticancer agents, and as a component of the blood-brain and blood-cerebrospinal fluid barriers for anticancer agents. In addition, we will complete our investigation of the newly discovered MRP family members by determining the drug resistance abilities and substrate selectivity of MRP9 - the only MRP whose functional properties have not been determined to any extent. These studies will provide insights into factors that reduce the effectiveness of chemotherapeutic agents, as well as into medically relevant physiological processes in which these unusual pumps are involved.

Public Health Relevance

The experiments in this proposal will promote public health by providing information on why many types of cancers are not successfully treated with anticancer agents. This information should assist in the development of agents and strategies that are more successful.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA073728-10
Application #
7849059
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
1999-09-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
10
Fiscal Year
2010
Total Cost
$418,535
Indirect Cost
Name
University of Illinois at Chicago
Department
Type
Other Domestic Higher Education
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Sane, Ramola; Wu, Shu-Pei; Zhang, Rong et al. (2014) The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain. Drug Metab Dispos 42:537-40
Gallo, J M (2013) Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. Clin Pharmacol Ther 93:236-8
Birtwistle, M R; Mager, D E; Gallo, J M (2013) Mechanistic vs. Empirical network models of drug action. CPT Pharmacometrics Syst Pharmacol 2:e72
Hopper-Borge, Elizabeth A; Churchill, Timothy; Paulose, Chelsy et al. (2011) Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 71:3649-57
Wang, Fan; Zhou, Feng; Kruh, Gary D et al. (2010) Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol 12:1043-9
Hopper-Borge, Elizabeth; Xu, Xiu; Shen, Tong et al. (2009) Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 69:178-84
Zhou, Ying; Hopper-Borge, Elizabeth; Shen, Tong et al. (2009) Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 77:993-1001
Guo, Yanping; Köck, Kathleen; Ritter, Christoph A et al. (2009) Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res 15:1762-9
Rao, Anuradha; Haywood, Jamie; Craddock, Ann L et al. (2008) The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A 105:3891-6
Risinger, April L; Jackson, Evelyn M; Polin, Lisa A et al. (2008) The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 68:8881-8

Showing the most recent 10 out of 32 publications